Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Senzime AB ( (SE:SEZI) ) just unveiled an announcement.
Senzime AB has welcomed new European pediatric guidelines recommending EMG-based neuromuscular monitoring during anesthesia, a technology utilized by their TetraGraph system. This development is significant for pediatric patient safety and presents new market opportunities for Senzime, as their system is specifically designed for pediatric use and is already in use at leading hospitals.
The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.00 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
More about Senzime AB
Senzime is a leading medical device company established in 1999, specializing in precision-based monitoring systems that enhance perioperative patient safety. Their flagship product, the TetraGraph® system, is renowned for its accuracy in monitoring neuromuscular transmission during surgery. Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market and the US OTCQX Market.
Average Trading Volume: 573,136
Technical Sentiment Signal: Sell
Current Market Cap: SEK979.4M
For a thorough assessment of SEZI stock, go to TipRanks’ Stock Analysis page.